Success Stories: Biotherapeutics Researcher from China Secures EB-2 NIW Approval

Case Summary:     

We are delighted to share the approval of an EB-2 National Interest Waiver (NIW) petition for a biotherapeutics-focused researcher originally from China. At the time of filing, the client was engaged as a Ph.D. candidate and graduate researcher, actively working on pivotal research in protein misfolding mechanisms with potential therapeutic applications.

Driving Advances in Misfolded Protein Research

The client’s proposed endeavor involves exploring the complexities of misfolded protein structures and advancing therapeutic strategies to mitigate the progression and cost of treating debilitating illnesses such as neurodegenerative disorders, cancer, and diabetes. By investigating the molecular processes that cause protein misfolding and identifying how these aberrant structures can be corrected or leveraged, the client’s work addresses an urgent scientific and public health need. His focus includes not only disease mechanisms but also the design of cost-effective treatment platforms grounded in structural biochemistry.

Proven Impact and Research Excellence

The petition demonstrated that the client had already made notable progress in this field, with four peer-reviewed journal articles published in top-ranking scientific journals and a total citation count of 91. His research has been cited by global peers tackling high-impact topics, including cancer therapies, cellular mechanotransduction, and protein quantification methods.

One of his most cited papers—published in Nature Chemistry—placed in the top 0.01% of its publication year for the field of Biology & Biochemistry, underscoring the influence and timeliness of his findings. Beyond publications, the client had performed at least five peer reviews, reflecting both his scholarly expertise and his contributions to maintaining research quality in the field.

Recognition and Independent Validation

Support letters from domain experts further emphasized the value of the client’s contributions. One such letter noted:

“His work has laid the groundwork for targeted therapeutic strategies by clarifying the proteostasis network’s interactions with misfolded proteins. This is a cornerstone in developing next-generation biologics.”

Such testimonies reaffirm the client’s national relevance and thought leadership in his area of specialization.

Positioned to Continue and Expand Impact

What made this petition particularly compelling was the alignment between the client’s background and his clearly articulated future research plans. His advanced education, hands-on experience with biophysical characterization techniques, and involvement in translational applications of protein chemistry demonstrated that he was well-positioned to continue advancing the field. His future research roadmap includes developing novel biotherapeutics to be applied across both academic and industrial R&D settings.

Additionally, the petition documented support from major U.S. funding agencies—including NIH, NSF, and DOD—which had backed related projects in his field. This federal interest in the broader area of his research further affirmed the endeavor’s national significance.

NIW Approval and Outlook

Thanks to the strength of his research record and the clear national importance of his work, the EB-2 NIW petition filed on October 18, 2023, was approved on July 30, 2025, without delay.

We are proud to have assisted this accomplished researcher in securing his EB-2 NIW approval and look forward to seeing the continued impact of his work in shaping the future of biotherapeutic innovation. As always, the North America Immigration Law Group (NAILG) remains committed to guiding extraordinary researchers and professionals through successful immigration pathways.